BofA analyst Geoff Meacham raised the firm’s price target on Regeneron to $720 from $710 and keeps an Underperform rating on the shares. The firm notes that it remains “skeptical” of the Eylea franchise outlook and that its estimates are below the Street for Q1 revenue and EPS, though it cites net cash for its increased target in a Large Cap Biotech and Pharma earnings preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron (NASDAQ:REGN) Accused of Manipulating Pricing
- DOJ files false claims act complaint against Regeneron over drug pricing
- Regeneron presents pivotal data from Phase 1/2 LINKER-MM1 trial of linvoseltamab
- Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
- LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
